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Multidrug resistance (MDR) is known to compromise treatment
of cancers with several structurally and functionally unrelated
anticancer drugs, including anthracyclines, vinca alkaloids,
epipodophyllotoxins, Paclitaxel, colchicine and actinomycin D.
Although there are several different mechanisms associated with
development of MDR, a common cause is believed to be over-
expression of a plasma membrane P-glycoprotein (P-gp). This 170
kDa protein is encoded by the MDR1 gene and acts as an energy-
dependent drug efflux pump, preventing adequate intracellular
accumulation of cytotoxic drugs (for reviews see Gottesman and
Pastan, 1993, Childs and Ling, 1994; Germann, 1996).
The first report of the pharmacological reversal of MDR was
made by Tsuruo and colleagues in 1981 (Tsuruo et al, 1981), who
showed that the calcium channel blocker verapamil and the
calmodulin antagonist trifluoperazine were able to potentiate the
cytotoxic effect of vincristine and produce an increased cellular
accumulation of vincristine in a murine MDR cell line. A large
number of lipophilic, positively charged compounds have subse-
quently been identified as MDR modulators, which function by
blocking P-gp-mediated drug efflux. The initial MDR modulators,
such as verapamil, cyclosporin A, FK506, quinine, trifluoperazine
and tamoxifen, were originally developed for pharmacological
uses other than inhibition of MDR. For many of these drugs, wide-
spread clinical use as MDR modulators has been precluded
because of side-effects associated with their use at concentrations
required to inhibit P-gp (Lum et al, 1993; Ferry et al, 1996).
However, some of these modulators, such as verapamil and
cyclosporin A, have shown clinical benefit in the treatment of
refractory haematopoietic malignancies (Dalton, 1994). Hence the
development of a more specific and potent modulator of MDR
seemed desirable. Indeed, recently, some potent second-generation
modulators have been developed and the most potent of these
include PSC 833 (Boesch et al, 1991), GF120918 (GG918) (Hyafil
et al, 1993) and LY335979 (Dantzig et al, 1996). Some of these
compounds are currently in clinical trials.
XR9051, a novel, potent and specific modulator of P-gp-medi-
ated MDR, was derived from the chemical modification of a lead
natural product diketopiperazine, isolated from a Streptomyces
species. In vitro, co-exposure to 300–500 nM XR9051 fully
reverses resistance to a range of cytotoxic drugs in several murine
and human P-gp-expressing cell lines (Dale et al, 1998). The
present studies were performed to evaluate the in vivo efficacy and
pharmacokinetic profile of XR9051. The results demonstrate that
XR9051 has a large volume of distribution, is well-absorbed orally
and is a potent modulator of MDR in vivo. The modulatory
activity was observed in several tumour models with a range of
cytotoxic agents at well-tolerated doses. Hence XR9051 could
potentially have significant clinical benefit in the treatment of
MDR cancers.
MATERIALS AND METHODS
Materials
Epirubicin and doxorubicin were obtained from Pharmatalia (St
Albans, UK). Paclitaxel and etoposide were purchased from
Bristol-Myers Squibb Pharmaceuticals Ltd (Middlesex, UK).
Vincristine was purchased from David Bull Laboratories
(Warwick, UK). 1,2-Propanediol (propylene glycol) and D-(+)-
glucose (dextrose) were obtained from Sigma UK Ltd. XR9051
was synthesized as a mesylate salt at Xenova Ltd and was dis-
solved in propylene glycol–5% dextrose (3/2, v/v) at 20 mg ml–1
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and diluted appropriately in 5% dextrose immediately before use.
All cytotoxic drugs were of clinical grade and were diluted to the
desired concentration in 0.9% sodium chloride solution or 5%
(w/v) dextrose solution. All solutions were kept in the dark.
In vivo efficacy evaluation
P388 murine leukaemia model
All animal experimentation was performed to Home Office regu-
lations and the UKCCCR guidelines were adhered to throughout
all anti-tumour studies. The P388/P-sensitive murine leukaemia
cell line and the P388/DX Johnson drug-resistant subline, derived
by continuous exposure to doxorubicin (Johnson et al, 1978) were
provided by Dr M Grandi (Pharmacia Upjohn, Milan, Italy). In
vitro both cell lines were maintained in RPMI-1640 medium
supplemented with 10% fetal calf serum (FCS), 2 mML -glutamine
and 6 mM 2-mercaptoethanol at 37°C in an atmosphere of 95%
air–5% CO2. Drug-resistant cells were maintained under positive
selective pressure by treatment with 0.25 mg ml–1 doxorubicin for
one passage out of every six to eight passages. These cells were
subsequently incubated in drug-free medium for one passage
before experimental use.
For in vivo studies cells were maintained by weekly intraperi-
toneal (i.p.) passage of 106 cells in 6–8-week-old female (C57BL/6
X DBA/2) F1 hybrid mice. The cells underwent a minimum of two
in vivo passages before use in efficacy studies and they were
discarded after 20 passages. Preliminary studies showed that
increasing the number of parental and resistant cells in the
inoculum from 101 to 105 cells progressively shortened survival
time of mice. Thereafter, no further decrease in survival time was
observed with increase in cell inoculum up to 107 cells. Hence for
efficacy studies, female F1 hybrid mice were inoculated with
105 P388/P or P388/DX Johnson cells i.p. in 1 ml of phosphate
buffered saline (PBS). Following cell inoculation (day 0), the
animals were randomized into groups of 8–12. The groups were
treated 24 h after cell inoculation with various schedules of
vincristine or doxorubicin with and without XR9051. Vincristine
(0.1 or 0.2 mg kg–1, in 10 ml kg–1) was administered i.p. on days
1–5 and doxorubicin (2 mg kg–1 in 10 ml kg–1) was administered
i.p. on days 1, 4 and 7 after cell inoculation. XR9051 was adminis-
tered either i.p. at the same time as, or intravenously (i.v.) or orally
(p.o.) 1 h before, the cytotoxic drugs. The animals were monitored
daily and killed by cervical dislocation when they became mori-
bund. Statistical evaluation of survival data was performed using
the Kaplan–Meier log-rank test.
MC26 murine colon carcinoma model
In vivo efficacy was also evaluated using MC26 murine colon
carcinoma tumours that exhibit intrinsic drug resistance which is
at least partly mediated by expression of P-gp (Spoelstra et al,
1991). The cell line, which grows in vitro as a loosely-attached
monolayer, was maintained in RPMI-1640 medium supplemented
with 10% FCS and 2 mML -glutamine at 37°C in an atmosphere of
95% air–5% CO2. The MC26 tumours were initially established by
subcutaneous (s.c.) injection of 1 ´ 105 cells into female Balb/c
mice. Once the tumours had reached a mean diameter of about
1 cm they were removed and minced, and a small portion of the
tumour slurry implanted s.c. in the right flank of female Balb/c
mice (age 8–12 weeks). The established tumours were similarly
passaged a minimum of two times before use in efficacy studies.
For the efficacy studies, tumour slurry was implanted (day 0) and
the animals randomized into groups of 15–20 prior to treatment
with various regimens 24 h later. XR9051 was administered i.p.
(20 mg kg–1) or p.o. (40 mg kg–1) 1 h before and 3 h after doxoru-
bicin i.v. (5 mg kg–1). The animals were weighed twice weekly and
on day 14 they were killed by cervical dislocation, the tumours
excised and weighed. Student’s t-test was used for statistical eval-
uation of the results.
Human carcinoma xenografts
The ability of XR9051 to improve anti-tumour activity of several
cytotoxic agents was evaluated using a number of human carci-
noma xenografts in which MDR was mediated by P-gp expression.
2780AD ovarian carcinoma xenografts
Efficacy studies in 2780AD ovarian carcinoma xenografts estab-
lished in athymic mice were performed as described by Plumb
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Figure 1 Sensitization of vincristine anti-tumour effect on P388/DX Johnson
murine leukaemia-bearing mice by XR9051 administered (A) i.v. and (B) p.o.
P388/DXJ cells (105) were implanted i.p. and treatment was started 24 h
later. The modulator was administered 1 h before the cytotoxic drug. (A)
Tumour-bearing mice were treated on days 1–5 with vincristine
0.1 mg kg–1 i.p. (l l), XR9051 40 mg kg–1 i.v. (l), or combination of vincristine
with XR9051 i.v. at 40 mg kg–1 (s), 20 mg kg–1 (t) or 10 mg kg–1 (u).
(B) Tumour-bearing mice were treated in days 1–5 with vincristine
0.1 mg kg–1 i.p. (l l), XR9051 80 mg kg–1 i.v. (u) and vincristine with XR9051
p.o. at 120 mg kg–1 (l), 80 mg kg–1 (s) or 60 mg kg–1 (t). Vehicle (n n) group.
All groups consisted of 8–12 animals. Groups treated with combination
schedules exhibited significantly increased survival (P < 0.01) compared to
those treated with cytotoxic drug alone1674 P Mistry et al
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et al (1994). Briefly, female mice bearing s.c. 2780AD tumours
with a mean diameter of 0.5–1.0 cm were randomized into groups
of 6. The animals were treated (day 0) with combinations of
XR9051 administered i.p. (20–40 mg kg–1) with epirubicin i.v.
(10 mg kg–1). The modulator was administered 2 h before and after
epirubicin. Both body weights and tumour diameters (two perpen-
dicular values measured using callipers) were recorded at least
twice a week. The tumour volume was estimated using spherical
geometry (volume = p/6 ´ d3, where d is the mean diameter).
CH1/DOXr ovarian carcinoma xenografts
CH1-sensitive and CH1/DOXr-resistant ovarian carcinoma cell
lines, obtained from Dr Lloyd Kelland (Institute of Cancer
Research, Sutton, UK), were also used for in vivo efficacy studies.
The cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% FCS and 2 mML -glut-
amine at 37°C in an atmosphere of 95% air–5% CO2. The tumours
were initially established s.c. by injection of 5 ´ 106 cells in
athymic mice. The tumours were subsequently passaged s.c. by
implantation of 1 mm3 pieces on both flanks of female athymic
mice aged 5–7 weeks. Mice bearing tumours with a mean diameter
of 0.4–0.7 cm were randomized into groups (6–10 tumours) and
treated with various regimens of modulator and cytotoxic agents
(see Results section). Tumour volume and body weights were
measured twice weekly post-treatment as outlined above.
H69/LX small cell lung carcinoma xenografts
The efficacy of XR9051 was also evaluated using the H69/LX
small cell lung carcinoma (SCLC) xenografts. The H69/LX and
H69/LX4 cells were obtained from Dr Peter Twentyman (Imperial
Cancer Research Fund, Cambridge, UK) and grown in vitro as
outlined previously (Twentyman et al, 1986). The H69/LX cell
xenografts were initially established by s.c. injection of 5 ´ 106
cells bilaterally in female athymic mice aged 5–7 weeks (ICR,
Sutton). The established tumours were passaged by bilateral s.c.
implantation of tumour tissue (1 mm3) and were used for efficacy
studies within ten passages. Animals bearing tumours with a mean
diameter of 0.4–0.7 cm were randomized into groups of 8–12
tumours, and treated with various regimens of XR9051 in combi-
nation with doxorubicin and vincristine. Day 0 was the start of
treatment. Tumour volume and body weights were measured twice
weekly post-treatment as outlined above. Statistical significance
was evaluated using the Mann–Whitney U-test (two tailed).
Pharmacokinetic studies with XR9051
Female Balb/c mice (20–25 g) were injected i.v. with XR9051
(20 mg kg–1) and at various times (5 min to 24 h) levels of the
modulator were determined in plasma, liver, heart and brain in
groups of three animals per time point. Blood was removed by
cardiac puncture, after induction of anaesthesia, using heparinized
syringes and centrifuged at 4°C to prepare plasma. The plasma and
tissue samples were stored at –40°C until analysis by high pressure
liquid chromatography (HPLC). Plasma levels of XR9051 at
various times (30 min to 24 h) were also determined following a
single oral dose of 50 mg kg–1 in Balb/c mice (groups of three). In
a separate experiment, levels of XR9051 in resistant H69/LX4
SCLC tumours were determined at various times following a
single i.v. dose of 20 mg kg–1 in tumour-bearing athymic mice.
The plasma samples at 4°C were extracted by addition of 3
volumes of –20°C methanol and incubation at –40°C for 15 min
before centrifuging in a microfuge. The tissue samples were homog-
enized in 2–5 volumes (w/v) of PBS (pH 7.4) at 4°C and aliquots
were extracted as described for plasma samples. The supernatants
were analysed by HPLC as follows: the samples were eluted through
an Inertsil ODS-2 column (250 ´ 4.6 mm) plus a guard column (10
´ 2 mm) using a linear gradient of 60% solvent A + 40% solvent B
to 100% solvent B. Solvent A and B consisted of 0.02 M triethylam-
monium acetate pH 4.1 and 80% acetonitrile in 0.02 M triethylam-
monium acetate pH 4.1, respectively. The flow rate was 1.0 ml min–1
and XR9051 was detected at 327 nm. The concentration of XR9051
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Figure 2 Sensitization of doxorubicin anti-tumour effect on MC26 mouse
colon carcinoma by XR9051 administered i.p. or p.o. Mice were implanted
with MC26 tumour slurry s.c. and treated 24 h later. The modulator was
administered i.p. or p.o. 1 h before and 3 h after doxorubicin i.v. (5 mg kg–1)
on day 1. The tumour weights were determined on day 14 after tumour
implant. Values represent mean ± S.E.M., using 20 animals per group.
Vehicle; vehicle + doxorubicin 5 mg kg–1 i.v.; doxorubicin + XR9051
20 mg kg–1 i.p. (P < 0.001); doxorubicin + XR9051 40 mg kg–1 p.o. (P <
0.001). The P-valves are in comparison with untreated animals or those
treated with doxorubicin alone
Figure 3 Effect of XR9051 on activity of epirubicin in mice bearing 2780AD
ovarian carcinoma xenografts. The modulator was administered i.p. 2 h
before and 2 h after epirubicin i.v. on day 0. Vehicle (l l), epirubicin
10 mg kg–1 i.v. (n n), XR9051 40 mg kg–1 i.p. (s), epirubicin + XR9051 i.p. at
20 mg kg–1(n), 30 mg kg–1 (t) and 40 mg kg–1 (l). Each group consisted of
six animals. Tumour growth rate in animals treated with epirubicin + XR9051
at all doses was significantly different (P < 0.01) from those treated with drug
alone or vehicleModulation of multidrug resistance by XR9051 1675
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in the samples was determined from standard curves prepared using
appropriate biological fluids. Pilot studies had shown that the
recovery of added XR9051 from plasma was > 95%. The limit of
quantitation in plasma samples was 50 ng ml–1 and in tissue samples
it was between 100 and 500 ng g–1.
RESULTS
Efficacy in P388 murine leukaemia model
The sensitive and MDR P388 murine leukaemia cells implanted i.p.
have been extensively used for evaluating the efficacy of MDR
modulators (Tsuruo et al, 1981; Shinoda et al, 1989; Boesch et al,
1991; Hyafil et al, 1993). We have shown in previous studies that in
vitro co-exposure to XR9051 fully restored sensitivity of the resis-
tant cells (P388/DX Johnson) to several cytotoxic agents (Dale et
al, 1998). The in vivo studies with P388/P-sensitive cells implanted
i.p. in mice demonstrated that i.p. administration of vincristine
(0.1 mg kg–1) on days 1–5 or doxorubicin (2 mg kg–1) on days 1, 4
and 7 after cell inoculation (day 0) significantly (P < 0.005)
increased the lifespan of tumour-bearing animals compared to
those treated with vehicle alone. Some drug-treated animals
survived for between 50 and > 60 days, whereas vehicle or modu-
lator alone treated animals survived for 12 days. Co-administration
of XR9051 (20 or 40 mg kg–1, i.v.) with either cytotoxic drug did
not further increase the lifespan of the sensitive tumour-bearing
animals. In contrast, treatment of P388/DX Johnson-resistant
leukaemia-bearing mice with vincristine or doxorubicin in the
absence of XR9051 had little or no effect on survival. However, co-
administration of XR9051 significantly increased anti-tumour
activity of both cytotoxic drugs in resistant tumour-bearing
animals. The increase in lifespan of resistant tumour-bearing
animals following treatment with combination schedules was not as
great as that achieved with cytotoxic drugs alone in sensitive
tumour-bearing animals. However, preliminary studies had shown
that this difference may be due to the fact that the resistant
P388/DX Johnson tumours were more aggressive and killed the
host animals faster than the parental P388 tumours. The data
suggested that the increase in survival time following identical cell
kill would be greater in animals bearing parental than those bearing
resistant tumours, and that the difference in survival time would
increase as the number of cells killed increased. The initial efficacy
studies in resistant leukaemia-bearing animals were performed
following i.p. co-administration of XR9051 at 5, 10 and 20 mg kg–1
with vincristine (0.1 mg kg–1, i.p.) and demonstrated a dose-depen-
dent increase in lifespan of resistant tumour-bearing animals (data
not shown). Subsequent studies were performed with combination
therapies in which XR9051 was administered at a site remote from
the tumour (i.v. or p.o.), which is more clinically relevant. Again,
significant dose-related increases in lifespan were observed when
XR9051 was administered either i.v. or p.o. 1 h before vincristine
on days 1–5, compared with cytotoxic drug alone (Figure 1A, B).
Similar results were obtained following i.v. and p.o. administration
of XR9051 with doxorubicin. Moreover, there was no significant
increase in toxicity, as assessed by body weight loss, in the combi-
nation therapy groups (data not shown). An equivalent enhance-
ment in anti-tumour activity of both cytotoxic drug was obtained
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Figure 4 Sensitization of Paclitaxel and etoposide anti-tumour effect on
CHI DOXr ovarian carcinoma xenografts by XR9051 administered i.v.
Animals bearing s.c. tumours were treated with 20 mg kg–1 i.p. Paclitaxel
alone (l l) or Paclitaxel + XR9051 10 mg kg–1 i.v. (l) on days 0, 2 and 4; or
30 mg kg–1 i.p. etoposide alone (u u) or etoposide + XR9051 at 20 mg kg–1 (u)
on days 0, 5 and 11; or 20 mg kg–1 i.v. XR9051 alone (s) or vehicle (n n) on
days 0, 2 and 4. Co-administration of XR9051 i.v. with Paclitaxel or etoposide
significantly reduced tumour growth rate compared to either cytotoxic drug or
vehicle alone (P < 0.01)
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Figure 5 (A) Effect of XR9051 on anti-tumour activity of vincristine in mice
bearing H69/LX SCLC xenografts. Animals bearing s.c. tumours were treated
with 0.5 mg kg–1 vincristine i.p. (l l) or XR9051 40 mg kg–1 i.p. 1 h before
vincristine (t) or XR9051 40 mg kg–1 p.o. 2 h before and 2 h after vincristine
(s); Vehicle (n n) group. (B) Animals bearing s.c. tumours were treated with
doxorubicin (4 mg kg–1 i.p.) (u u) or XR9051 40 mg kg–1 i.p. 1 h before
doxorubicin (t) or XR9051 40 mg kg–1 p.o. 2 h before and 2 h after
doxorubicin (s); vehicle (n n). Tumour growth rate was significantly (P < 0.01)
reduced in animals treated with combination schedules compared with drug
alone1676 P Mistry et al
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when the oral dose of XR9051 was two- to threefold greater than
the i.v. dose. Administration of XR9051 alone by any route had no
effect on survival of mice bearing sensitive or resistant tumours.
These results are consistent with the in vivo modulatory activity
being through inhibition of P-gp function.
MC26 murine colon carcinoma studies
In vitro, 500 nM XR9051 enhanced the sensitivity of the intrinsi-
cally resistant MC26 cells to doxorubicin by three-fold (unpub-
lished data). The ability of XR9051 to potentiate the anti-tumour
activity of doxorubicin against s.c. MC26 tumours is shown in
Figure 2. Treatment was started 24 h after tumour implanta-
tion. Administration of XR9051 either i.p. (20 mg kg–1) or p.o.
(40 mg kg–1) at 0 and 4 h with doxorubicin (5 mg kg, i.v.) at 1 h
resulted in significant (P < 0.001) inhibition of tumour growth on
day 14 compared to cytotoxic drug alone. XR9051 alone had no
significant inhibitory activity in pilot experiments. In addition,
there were no differences in body weight gain between the various
groups.
Efficacy in human carcinoma xenografts
The ability of XR9051 to reverse P-gp-mediated MDR was evaluated
in several human carcinoma xenografts grown s.c. in athymic mice.
Figure 3 demonstrates that co-administration of XR9051 (i.p.) with
epirubicin (10 mg kg–1, i.v.) significantly reduced growth rate of
MDR 2780AD ovarian carcinoma xenografts compared with either
drug alone. Moreover, the potentiation of epirubicin anti-tumour
activity was related to the dose of XR9051. The reduction in resistant
tumour growth rate obtained by co-administration of 40 mg kg–1
XR9051 was similar to that reported for the sensitive (2780) tumours
following epirubicin treatment alone (Plumb et al, 1994), suggesting
that full reversal of resistance was achieved with this combination
therapy. The weight loss observed in groups treated with epirubicin
plus XR9051 was similar to that observed in the group treated with
cytotoxic drug alone (data not shown).
Studies in another MDR ovarian carcinoma (CH1/Doxr)
xenograft showed that administration of Paclitaxel (20 mg kg–1,
i.p.) or etoposide (30 mg kg–1, i.p.) with XR9051 i.v., 10 or
20 mg kg–1, respectively (Figure 4) significantly reduced tumour
growth rate compared with either drug alone and that the combina-
tion schedules were well-tolerated as judged by changes in body
weights (data not shown). The reduction in growth rate of the
resistant tumour was similar to that observed with the cytotoxic
drug alone in the sensitive tumours (data not shown). Similarly,
administration of XR9051 i.p. or p.o. significantly potentiated the
anti-tumour activity of vincristine (0.5 mg kg–1, i.p.) (Figure 5A)
and doxorubicin (2 mg kg–1) (Figure 5B) in H69/LX SCLC
xenografts. Again the combination schedules were well-tolerated.
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Figure 6 (A) Concentration versus time curves obtained for XR9051 in plasma (n), liver (l), heart (s) and brain (t) after i.v. dose of 20 mg kg–1 in Balb/c mice.
(B) Levels of XR9051 in H69/LX4 multidrug-resistant human SCLC tumours after an i.v. dose of 20 mg kg–1 in tumour-bearing nude mice. (C) Concentration
versus time profile of XR9051 in plasma after p.o. administration of 50 mg kg–1 in Balb/c mice. The values represent mean ± s.e.m of 3–5 animals per time pointPharmacokinetics of XR9051
The concentration time curves for XR9051 as determined in
plasma, liver, heart and brain after a single i.v. dose of 20 mg
kg–1 are shown in Figure 6A. Using a two-compartment model the
apparent elimination half-life for XR9051 in plasma, liver, heart
and brain was 3.96, 4.93, 2.00 and 1.15 h respectively. The steady-
state volume of distribution for XR9051 was 9.6 l kg–1 and the
high concentrations of the compound in tissues are consistent with
this large volume of distribution. The area under the concentration
time curves (AUC) from time 0–∞ for plasma was 11.9 mg. hml–1
The ratio between AUC for tissue:plasma for liver, heart and brain
were 79.6, 16.9 and 0.3 respectively. The intravenous pharmaco-
kinetic parameters were linear between 20 and 100 mg kg–1 doses
(data not shown). In a separate experiment, in H69/LX4 SCLC
xenograft-bearing athymic mice, a maximum concentration of
6.94 mg g–1 (9.4 mM) of XR9051 in tumour tissue was observed 1.5
h after a single i.v. dose of 20 mg kg–1 (Figure 6B). This concentra-
tion was well above that observed in plasma at the same time. The
apparent elimination half-life of the compound in tumour tissue
was 8.79 h and the AUC0–∞ was 57.1 mg. h ml–1. Following
oral administration of 50 mg kg–1 XR9051 Cmax in plasma was
1.3 mg ml –1 (1.8 mM) and Tmax was estimated to be 3.4 h (Figure
6C). The AUC0–24 h was 13.5 mg. h ml–1 and the oral bioavailability
of XR9051 was estimated to be about 46%.
DISCUSSION
Although a number of first-generation compounds have been
reported to reverse P-gp-mediated multidrug resistance in vitro,
few have shown beneficial effects in vivo in MDR tumour-bearing
animals due to lack of potency. The present in vivo studies with
XR9051 have shown that this modulator is potent and well-
tolerated at effective doses. These results are in agreement with the
in vitro results (Dale et al, 1998). Co-administration of XR9051
has shown clear dose-dependent enhancement of anti-tumour
activity of five cytotoxic agents (vincristine, doxorubicin, epiru-
bicin, Paclitaxel and etoposide) in mice bearing both murine and
human tumour xenografts exhibiting multidrug resistance.
Moreover, efficacy has been observed following both parenteral
(i.p. and i.v.) and oral routes of administration of modulator.
In the P388/MDR tumour-bearing animals the anti-tumour
activity of vincristine and doxorubicin was significantly increased
in a dose-dependent manner by i.v. (between 10 and 40 mg kg–1)
and oral (60–120 mg kg–1) co-administration of XR9051. In
contrast, cyclosporin A (CsA) at its maximum tolerated oral dose
in combination with vincristine did not enhance the activity of this
drug in these animals (data not shown). Boesch et al (1991) have
also reported no enhancement of vinblastine activity by co-admin-
istration of CsA orally in MDR P388 tumour-bearing animals.
However, CsA administered i.p. was reported to increase
vincristine anti-tumour activity in animals inoculated with P388
cells that had been transfected with the human MDR1 gene (Yang
et al, 1994). The resistance factor of this cell line to vincristine was
low (22-fold) compared to the cell line used in our studies
(70-fold). Several second-generation MDR modulators have been
reported to exhibit in vivo efficacy in murine tumour models
including MS-209 (Sato et al, 1995), S9788 (Cros et al, 1992), the
non-immunosuppressive cyclosporine A analogue, PSC 833,
which showed significant oral activity (Boesch et al, 1991),
GG918 (Hyafil et al, 1993) and LY335979 (Dantzig et al, 1996).
However, direct comparison of the potency between modulators
is difficult due to differences in tumour growth rates, treatment
schedules and experimental design.
In addition to the murine tumour models, XR9051 showed
significant modulatory activity in mice bearing MDR human
ovarian (2780AD and CH1/DOXr) and SCLC (H69/LX)
xenografts. Either complete or near complete reversal of resistance
to vincristine, doxorubicin, epirubicin, Paclitaxel and etoposide
was achieved in these models by co-administration of XR9051
either parenterally or orally at doses that were well-tolerated (acute
toxicity studies with XR9051 alone in mice showed no lethality
following 75 mg kg–1 i.v. and 2000 mg kg–1 p.o. dose). Moreover,
the combination therapy schedules were well-tolerated. The oral
potency of XR9051 was two- to three-fold less than that observed
following i.v. administration in these and the murine tumour
models. This correlates well with the oral bioavailability of
XR9051.
The in vivo potency of XR9051 correlates well with the phar-
macokinetic profile of the modulator, which shows that, following
i.v. administration, the compound rapidly distributes and accumu-
lates in tissues and has a long elimination half-life. In fact, over a
25 h period after a single i.v. dose of 20 mg kg–1 XR9051, concen-
trations in H69/LX4 MDR tumours (range 0.6–9.4 mM) remain
above levels required for full reversal of resistance in vitro
(300–500 nM). The in vivo efficacy of MDR modulators may be
due indirectly through an increase in pharmacokinetics of the cyto-
toxic agents as a result of reduced elimination or metabolism
(Wacher et al, 1995; Colombo et al, 1996). Indeed, such changes
are thought to be at least partially responsible for efficacy of some
modulators, such as CsA and PSC 833, but not others such as
GG918 and S9788 (Hyafil et al, 1993; Colombo et al, 1996). We
are currently determining the effects of XR9051 on pharmaco-
kinetics of cytotoxic agents and these studies will be reported
separately.
In conclusion, these results show that XR9051 is a potent and
specific modulator of P-gp-dependent MDR in vivo. It restores
sensitivity of syngeneic and human tumour xenografts to a range
of cytotoxic agents at doses that are well-tolerated. The data
reported here fully support our previous results demonstrating that
XR9051 (300–500 nM) fully sensitized a panel of resistant cells to
a broad range of cytotoxic drugs (Dale et al, 1998). Furthermore,
the activity of XR9051 persisted in vitro for an extended period
following removal from the culture medium. This feature should
give the modulator a significant advantage for clinical administra-
tion. Thus the in vitro and in vivo activity of XR9051 together with
its pharmacokinetic profile suggest that XR9051 may significantly
improve treatment of MDR cancers.
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